Patent intelligence · US
US 9161990
Hydrochloride salts of a glycopeptide-cephalosporin antbiotic compond
Hydrochloride salts of a glycopeptide-cephalosporin antbiotic compond
Patent details — US 9161990
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 20, 2015
- Expiration
- Oct 15, 2035
- Applicant
- THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
- Claims
- 15
- CPC classes
- A61K, A61K38/14, A61K47/64, A61P
Quick answer
US 9161990 (Hydrochloride salts of a glycopeptide-cephalosporin antbiotic compond) is held by THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC. Status: granted. Granted Oct 20, 2015. Expires Oct 15, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K38/14, A61K47/64, A61P, A61P31/04
More from THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12384761
Imidazolo indazole compounds as JAK inhibitors
granted -
US 12358931
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
granted -
US 12351561
Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 12285417
Methods for treating chronic obstructive pulmonary disease
granted -
US 12258316
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 12239638
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
granted -
US 12172994
Pyrimidine compound as JAK kinase inhibitor
granted -
US 12122773
Crystalline hydrate of a JAK inhibitor compound
granted
Frequently asked questions
What is US patent 9161990?
US 9161990 (Hydrochloride salts of a glycopeptide-cephalosporin antbiotic compond) is held by THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC. Status: granted. Granted Oct 20, 2015. Expires Oct 15, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9161990?
THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 635 pharmaceutical patents for this assignee.
When does US 9161990 expire?
Our index shows an expiration date of Oct 15, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.